These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25141341)

  • 1. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.
    Bhat R; Tummalapalli SR; Rotella DP
    J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 90: inhibitors in clinical trials.
    Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
    J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
    [No Abstract]   [Full Text] [Related]  

  • 4. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
    Chiosis G; Caldas Lopes E; Solit D
    Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors--potential therapeutics in cancer and neurodegeneration.
    Kitson RR; Moody CJ
    Chem Commun (Camb); 2013 Oct; 49(76):8441-3. PubMed ID: 23770604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based and in silico design of Hsp90 inhibitors.
    Sgobba M; Rastelli G
    ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
    Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
    J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
    Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein chaperones as anticancer therapy targets.
    Sausville E
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):92-3. PubMed ID: 16163168
    [No Abstract]   [Full Text] [Related]  

  • 17. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
    Wang Y; McAlpine SR
    Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
    Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
    Siegelin MD
    Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.